Manifold Biotechnologies Inc. has signed a strategic research collaboration and license agreement with F. Hoffmann-La Roche Ltd. to develop next-generation brain shuttles for neurological diseases. The collaboration will apply Manifold’s proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine.
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images.
Scientists in the U.K. are developing glucose-powered bioelectronics to advance the use and capabilities of implantable medical devices. A research team, led by the University of Bath, received £2.1 million (US$3.3 million) in funding from the government to develop miniature, lightweight and long-lasting glucose fuel cells to help address the invasiveness and limitations of current battery-powered implants.
Neurodegeneration specialist Vesper Bio ApS has announced positive results from the phase Ib/II trial of its oral sortilin inhibitor VES-001 in frontotemporal dementia. The small study involved six participants who had not progressed to symptomatic disease but were carriers of mutations in the GRN gene that codes for progranulin, a growth factor that is essential for neuronal health.
SK Biopharmaceuticals Co. Ltd. has identified sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers reported to be useful for the treatment of neuropathic pain.
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images.
Lumosa Therapeutics Co. Ltd.’s intravenous odatroltide (LT-3001) met the primary endpoints in a phase IIb trial in China in patients with acute ischemic stroke, paving the way for a pivotal phase III study.
Genescience Pharmaceuticals Co. Ltd. has disclosed tachykinin NK3 receptor (TACR3) antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), cancer, convulsions, depression and more.
RSS
